2X1:ETR
Abivax SA
€83.55
arrow_downward
-0.71%(-0.60) 1 日
10月2日, 17:35:35 GMT+2 · EUR
search
すべての記号
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto2X1 の上位の分析情報を生成しています...
始値
€83.15
高値
€84.50
安値
€83.00
時価総額
71.96億
平均出来高
1779.00
取引量
842.00
52 週高値
€137.40
52 週安値
€60.85
EPS
-€5.20
従業員数
98
始値
€83.15
高値
€84.50
安値
€83.00
時価総額
71.96億
平均出来高
1779.00
取引量
842.00
52 週高値
€137.40
52 週安値
€60.85
EPS
-€5.20
従業員数
98
ニュース記事
情報源: ウェブソース、ニュース パートナー
プロフィール
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA について